Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
gut microbiota1104 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A14561 | 29353414 | Probiotics Antimicrob Proteins | Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats. | 2019 | Details |
| A14698 | 29286050 | Nat Rev Endocrinol | Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. | 2017 | Details |
| A14730 | 29268121 | J Nutr Biochem | Age-dependent alterations of glucose clearance and homeostasis are temporally separated and modulated by dietary fat. | 2017 | Details |
| A14746 | 29259643 | Evid Based Complement Alternat Med | Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier. | 2017 | Details |
| A14849 | 29204141 | Front Microbiol | Flos Lonicera Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation. | 2017 | Details |
| A14876 | 29195686 | Trends Endocrinol Metab | Role of Bile Acids in Metabolic Control. | 2017 | Details |
| A14896 | 29187142 | BMC Gastroenterol | Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis. | 2017 | Details |
| A14931 | 29167659 | Front Microbiol | Balancing Herbal Medicine and Functional Food for Prevention and Treatment of Cardiometabolic Diseases through Modulating Gut Microbiota. | 2017 | Details |
| A14985 | 29139555 | Br J Pharmacol | Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. | 2018 | Details |
| A15043 | 29120742 | Cell Host Microbe | The Human Microbiome and Obesity: Moving beyond Associations. | 2017 | Details |
| A15064 | 29113135 | Nutrients | Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15090 | 29101772 | Rom J Intern Med | Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. | 2018 | Details |
| A15092 | 29100781 | Steroids | Estrogens and female liver health. | 2017 | Details |
| A15130 | 29083037 | Aliment Pharmacol Ther | Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. | 2017 | Details |
| A15136 | 29080046 | Curr Gastroenterol Rep | The Microbiome That Shapes Us: Can It Cause Obesity? | 2017 | Details |
| A15144 | 29075899 | J Gastroenterol | Immunoglobulin A and liver diseases. | 2017 | Details |
| A15162 | 29066788 | Sci Rep | Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. | 2017 | Details |
| A15163 | 29066462 | Am J Physiol Endocrinol Metab | Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. | 2017 | Details |
| A15167 | 29065507 | Nutrients | Fatty Acids Consumption: The Role Metabolic Aspects Involved in Obesity and Its Associated Disorders. | 2017 | Details |
| A15219 | 29038503 | Nat Commun | Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. | 2017 | Details |
| A15228 | 29035308 | Nutrients | Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. | 2017 | Details |
| A15230 | 29034439 | Indian J Gastroenterol | Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. | 2017 | Details |
| A15243 | 29025734 | Am J Physiol Gastrointest Liver Physiol | Dietary copper-fructose interactions alter gut microbial activity in male rats. | 2017 | Details |
| A15273 | 28990516 | Curr Med Chem | Gut Microbiota as a Therapeutic Target for Metabolic Disorders. | 2018 | Details |
| A15282 | 28988228 | J Pediatr Endocrinol Metab | The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. | 2017 | Details |
| A15291 | 28983453 | Curr Pharmacol Rep | Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. | 2017 | Details |
| A15305 | 28972878 | Discov Med | Role of nutrition, gene polymorphism, and gut microbiota in non-alcoholic fatty liver disease. | 2017 | Details |
| A15313 | 28970836 | Front Immunol | Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease. | 2017 | Details |
| A15318 | 28970141 | Hum Pathol | Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. | 2017 | Details |
| A15405 | 28927250 | Minerva Gastroenterol Dietol | Gut microbiota and the liver. | 2017 | Details |
| A15406 | 28927249 | Minerva Gastroenterol Dietol | Gut microbiota, obesity and metabolic disorders. | 2017 | Details |
| A15422 | 28921469 | Adv Exp Med Biol | Microbial Factors in Inflammatory Diseases and Cancers. | 2017 | Details |
| A15495 | 28876011 | Food Funct | A study of the prebiotic-like effects of tomato juice consumption in rats with diet-induced non-alcoholic fatty liver disease (NAFLD). | 2017 | Details |
| A15498 | 28875318 | Eur J Nutr | Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. | 2017 | Details |
| A15565 | 28840809 | Microbiol Spectr | Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. | 2017 | Details |
| A15566 | 28840806 | Microbiol Spectr | Microbiota, Liver Diseases, and Alcohol. | 2017 | Details |
| A15596 | 28823367 | Hepatobiliary Pancreat Dis Int | Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. | 2017 | Details |
| A15671 | 28774887 | Gut | Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. | 2017 | Details |
| A15681 | 28767077 | Children (Basel) | Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. | 2017 | Details |
| A15704 | 28751453 | J Endocrinol | Maternal modifiers of the infant gut microbiota: metabolic consequences. | 2017 | Details |
| A15751 | 28728746 | Am J Pathol | Linking Sex Differences in Non-Alcoholic Fatty Liver Disease to Bile Acid Signaling, Gut Microbiota, and High Fat Diet. | 2017 | Details |
| A15796 | 28705785 | Turk J Gastroenterol | Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis. | 2017 | Details |
| A15829 | 28691342 | Mol Nutr Food Res | Dual function of Lactobacillus kefiri DH5 in preventing high-fat-diet-induced obesity: direct reduction of cholesterol and upregulation of PPAR-α in adipose tissue. | 2017 | Details |
| A15920 | 28652650 | World J Gastroenterol | Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. | 2017 | Details |
| A15946 | 28641031 | Expert Opin Drug Saf | Treatment options for nonalcoholic steatohepatitis - a safety evaluation. | 2017 | Details |
| A15973 | 28632181 | Nutrients | Spirulina Protects against Hepatic Inflammation in Aging: An Effect Related to the Modulation of the Gut Microbiota? | 2017 | Details |
| A15995 | 28621554 | Expert Rev Gastroenterol Hepatol | Gut microbiota changes and chronic hepatitis C virus infection. | 2017 | Details |
| A16017 | 28609252 | Gut Microbes | Fecal microbiota transplantation in metabolic syndrome: History, present and future. | 2017 | Details |
| A16094 | 28573213 | ACS Cent Sci | Chemoproteomic Profiling of Bile Acid Interacting Proteins. | 2017 | Details |
| A16125 | 28550391 | Hepatol Int | Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. | 2017 | Details |
| A16133 | 28545373 | Curr Med Chem | Modulation of Aquaporins by Dietary Patterns and Plant Bioactive Compounds. | 2019 | Details |
| A16145 | 28539915 | Front Microbiol | The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease. | 2017 | Details |
| A16158 | 28533304 | J Lipid Res | Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. | 2017 | Details |
| A16174 | 28521872 | Metabolism | Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. | 2017 | Details |
| A16229 | 28497760 | Lancet Gastroenterol Hepatol | The intestinal microbiome and paediatric liver disease. | 2017 | Details |
| A16247 | 28484247 | Sci Rep | Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. | 2017 | Details |
| A16306 | 28467925 | Cell Metab | Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16342 | 28446519 | Diabetes | Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis, Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia. | 2017 | Details |
| A16381 | 28426878 | Carcinogenesis | Microbiota, NASH, HCC and the potential role of probiotics. | 2017 | Details |
| A16387 | 28425154 | Hepatol Res | Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. | 2017 | Details |
| A16402 | 28416740 | Oncotarget | Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease. | 2017 | Details |
| A16436 | 28389566 | J Biol Chem | Microbial metabolites in health and disease: Navigating the unknown in search of function. | 2017 | Details |
| A16443 | 28384519 | J Nutr Biochem | Kefir alleviates obesity and hepatic steatosis in high-fat diet-fed mice by modulation of gut microbiota and mycobiota: targeted and untargeted community analysis with correlation of biomarkers. | 2017 | Details |
| A16502 | 28349964 | Sci Rep | Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. | 2017 | Details |
| A16503 | 28349245 | J Gastroenterol | Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. | 2017 | Details |
| A16516 | 28345673 | Sci Rep | Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes. | 2017 | Details |
| A16521 | 28341485 | Biochim Biophys Acta Gen Subj | Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. | 2017 | Details |
| A16578 | 28298269 | Adv Nutr | Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. | 2017 | Details |
| A16600 | 28290049 | Curr Diab Rep | Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. | 2017 | Details |
| A16601 | 28288414 | Redox Biol | Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells. | 2017 | Details |
| A16664 | 28257306 | Curr Opin Gastroenterol | Intestinal microbiota and nonalcoholic steatohepatitis. | 2017 | Details |
| A16673 | 28253210 | Eur J Gastroenterol Hepatol | The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. | 2017 | Details |
| A16680 | 28249275 | Dig Dis | Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease. | 2017 | Details |
| A16696 | 28239368 | Front Endocrinol (Lausanne) | Connection of Nicotine to Diet-Induced Obesity and Non-Alcoholic Fatty Liver Disease: Cellular and Mechanistic Insights. | 2017 | Details |
| A16738 | 28215516 | Dig Liver Dis | AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. | 2017 | Details |
| A16740 | 28214524 | Gastroenterology | Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16751 | 28210913 | Int Urol Nephrol | Dietary and commercialized fructose: Sweet or sour? | 2017 | Details |
| A16802 | 28164848 | Gastroenterol Clin North Am | Gut Microbiota and Complications of Liver Disease. | 2017 | Details |
| A16900 | 28104981 | World J Gastroenterol | Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. | 2017 | Details |
| A16933 | 28086768 | BMC Complement Altern Med | Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. | 2017 | Details |
| A17096 | 27995280 | Arch Toxicol | Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). | 2016 | Details |
| A17208 | 27913996 | Dig Dis Sci | Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models. | 2016 | Details |
| A17214 | 27909908 | Recent Results Cancer Res | Obesity and Liver Cancer. | 2017 | Details |
| A17235 | 27895587 | Front Physiol | Vitamin D Signaling through Induction of Paneth Cell Defensins Maintains Gut Microbiota and Improves Metabolic Disorders and Hepatic Steatosis in Animal Models. | 2016 | Details |
| A17246 | 27890642 | Free Radic Biol Med | Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. | 2016 | Details |
| A17267 | 27879962 | Minerva Endocrinol | Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. | 2016 | Details |
| A17394 | 27780972 | Nat Rev Gastroenterol Hepatol | Developmental origins of NAFLD: a womb with a clue. | 2016 | Details |
| A17403 | 27656762 | Gut Microbes | Hypogonadism alters cecal and fecal microbiota in male mice. | 2016 | Details |
| A17570 | 27741171 | J Clin Gastroenterol | Gut Microbiota and the Liver: A Tale of 2 Cities: A Narrative View in 2 Acts. | 2017 | Details |
| A17652 | 27688650 | World J Gastroenterol | Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. | 2016 | Details |
| A17653 | 27686615 | Am J Physiol Gastrointest Liver Physiol | Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. | 2016 | Details |
| A17683 | 27660122 | Diabetes Care | Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. | 2016 | Details |
| A17713 | 27639801 | Gastroenterology | An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. | 2016 | Details |
| A17756 | 27617201 | Mol Metab | Non-alcoholic fatty liver and the gut microbiota. | 2016 | Details |
| A17830 | 27548720 | Dig Dis | Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. | 2016 | Details |
| A17862 | 27515958 | Rev Recent Clin Trials | Gut Microbiota and Alcoholic Liver Disease. | 2016 | Details |
| A17910 | 27483246 | Int J Mol Sci | The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. | 2016 | Details |
| A17929 | 27470892 | Zhonghua Gan Zang Bing Za Zhi | [Influence of gut microecology on the pathogenesis and treatment of nonalcoholic fatty liver disease]. | 2016 | Details |
| A18020 | 27409822 | Endocr Pract | GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN MANAGEMENT OF OBESITY AND PREDIABETES: REVIEW OF RANDOMIZED CONTROLLED TRIALS. | 2016 | Details |
| A18056 | 27380600 | J Pediatr Gastroenterol Nutr | Pediatric NAFLD: the Future role of Patient-Tailored Probiotics Therapy. | 2016 | Details |